Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
This study includes patients affected by advanced and resectable rectal adenocarcinoma. It
provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by
Chemoradiotherapy plus Bevacizumab. Surgery with total mesorectal incision must be performed
within 7-9 weeks after this last treatment. The protocol will be evaluate the disease free
survival at two years. Translational analyses will be performed to show the presence of VEGF
polymorphism, CD133 surface markers on colorectal CSCs.